Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2007

View Archived Issues

HDL mimetic CSL-111 shown to reduce atherosclerotic burden in the ERASE trial

Valortim demonstrates therapeutic effect in new primate model of anthrax

Plant-derived vaccine adjuvant shows enhanced immune response against hepatitis B in mice

Avanir provides business update

Phase II study of incyclinide in acne studies 40 mg dose

PRX-00023 studied in new phase IIb trial for major depressive disorder

FDA requires additional phase III study for cintredekin besudotox

Phase I/II data for Baxter's adjuvant-free pandemic H5N1 influenza vaccine

Hollis-Eden files IND to begin clinical testing of HE-3286 for metabolic disorders

European orphan drug status for Elafin

Udenafil demonstrates efficacy in erectile dysfunction phase IIb study

Structure and biological evaluation of CKD-501 presented at the ACS meeting

Novel glucocorticoid receptor modulator profiled at Merck

Provenge recommended for approval for prostate cancer

New data presented for bifeprunox

CanBas and Takeda collaborate in cancer

Aska licenses rights to JCR's recombinant FSH

PC-190708: a novel DNA gyrase B inhibitor identified at Prolysis

New agents for treating extrapyramidal disorders disclosed in recent Kissei patents

Recent patents report novel therapeutic agents for metabolic disorders

Recent Pfizer patent discloses new treatments for attention deficit hyperactivity disorder

Ceprotin approved for severe congenital protein C deficiency

Novartis suspends U.S. sales of Zelnorm

Janumet receives FDA approval

Lapatinib filed for approval in Japan for advanced breast cancer

Abbott seeks U.S. and E.U. approval of Humira for chronic plaque psoriasis

Twinrix approved for new accelerated dosing schedule

Exjade filed in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...